Literature DB >> 6175456

Interferon production of vitro by leucocytes from patients with systemic lupus erythematosus and rheumatoid arthritis.

P A Neighbour, A I Grayzel.   

Abstract

The production of interferons (IFN) by peripheral blood leucocytes from normal donors an patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) has been investigated in response to several IFN inducers in vitro. Whereas IFN responses of RA donors did not differ significantly from the normal group, those of SLE patients were significantly reduced, and many of these patients failed to respond to all. Patients with active or acute SLE responded significantly less well than those with inactive disease. There was no apparent effect of steroid therapy on the IFN responses of either SLE or RA patients. These data may indicate a basic immunological defect of the circulating leucocytes of SLE patients, which may be responsible for some of the in vitro lymphocyte anomalies reported for this disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6175456      PMCID: PMC1537416     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  Interferon production by lymphocytes from patients with systemic lupus erythematosus.

Authors:  D Alarcón-Segovia; J Ruiz-Gómez; E Fishbein; M E Bustamante
Journal:  Arthritis Rheum       Date:  1974 Sep-Oct

3.  In vitro leukocyte interferon production in patients with Hodgkin's disease.

Authors:  A L Rassiga-Pidot; O R McIntyre
Journal:  Cancer Res       Date:  1974-11       Impact factor: 12.701

4.  Interferon production by human leucocytes in vitro. Reduced levels in lymphatic leukemia.

Authors:  S H Lee; R L Ozere; C E Van Rooyen
Journal:  Proc Soc Exp Biol Med       Date:  1966-05

5.  Leukocyte interferon production, RNA synthesis, and PHA response in patients with infectious mononucleosis.

Authors:  A L Pidot; L H Maurer; O R McIntyre
Journal:  Blood       Date:  1973-08       Impact factor: 22.113

6.  Depression of cellular-mediated immunity in systemic lupus erythematosus. relation to disease activity.

Authors:  C J Rosenthal; E C Franklin
Journal:  Arthritis Rheum       Date:  1975 May-Jun

7.  Target cells for interferon production in human leukocytes stimulated by sendai virus.

Authors:  T Yamaguchi; K Handa; Y Shimizu; T Abo; K Kumagai
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

8.  Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus.

Authors:  B Bresnihan; H E Jasin
Journal:  J Clin Invest       Date:  1977-01       Impact factor: 14.808

9.  Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis.

Authors:  G Trinchieri; D Santoli
Journal:  J Exp Med       Date:  1978-05-01       Impact factor: 14.307

10.  Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Identification of the anti-viral activity as interferon and characterization of the human effector lymphocyte subpopulation.

Authors:  G Trinchieri; D Santoli; R R Dee; B B Knowles
Journal:  J Exp Med       Date:  1978-05-01       Impact factor: 14.307

View more
  18 in total

Review 1.  Natural killer cells and autoimmunity.

Authors:  E Grunebaum; E Malatzky-Goshen; Y Shoenfeld
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

2.  Isolated adrenocorticotropic hormone deficiency associated with common variable immunodeficiency.

Authors:  P A Tovo; R Lala; S Martino; G Pastorelli; C De Sanctis
Journal:  Eur J Pediatr       Date:  1991-04       Impact factor: 3.183

3.  Increased activity of oligo-2',5'-adenylate synthetase in Down's syndrome and epilepsy.

Authors:  N Fujii; K Oguma; M Fujii; R Fukatsu; N Takahata; M Kitabatake
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

4.  Serum levels of interferons in patients with systemic lupus erythematosus.

Authors:  T Kim; Y Kanayama; N Negoro; M Okamura; T Takeda; T Inoue
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

5.  Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis.

Authors:  K Hildner; S Finotto; C Becker; J Schlaak; P Schirmacher; P R Galle; E Märker-Hermann; M F Neurath
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

6.  Interferon deficiency syndrome.

Authors:  S Levin; T Hahn
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

7.  Fate of herpes simplex virus in lymphocytes from blood and joint effusions of systemic and pauciarticular juvenile chronic arthritis.

Authors:  P Hollingworth; D J Appleford; B M Ansell; A M Denman
Journal:  Ann Rheum Dis       Date:  1983-02       Impact factor: 19.103

8.  Synthesis of intrathecal interferon in systemic lupus erythematosus with neurological complications.

Authors:  P Lebon; G R Lenoir; A Fischer; A Lagrue
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-22

9.  Reduced killer cell activity of lymphocytes from patients with asbestosis.

Authors:  M Kubota; S Kagamimori; K Yokoyama; A Okada
Journal:  Br J Ind Med       Date:  1985-04

10.  Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers.

Authors:  W L Sibbitt; P M Mathews; A D Bankhurst
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.